Search clinical trials for: six courses of zanubrutinib, rituximab and lenalidomide

Total 4473 results

Ruijin Hospital
The First Affiliated Hospital of Nanchang University; Qilu Hospital of Shandong... and other collaborators

Recruiting

The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years

Diffuse Large B-Cell Lymphoma

China
Henan Cancer Hospital

Recruiting

Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma

Central Nervous System Lymphoma

China
Qingdao Central Hospital

Recruiting

Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial

Overall Survival

China
Ruijin Hospital

Active, not recruiting

Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B Cell Lymphoma

China
Zhejiang Cancer Hospital

Recruiting

ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL

Diffuse Large B Cell Lymphoma

China
First Affiliated Hospital of Wenzhou Medical University

Recruiting

The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.

Diffuse Large B Cell Lymphoma

China
MD Anderson International Spain SA
Celgene Corporation

Completed

Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia (LLC-LENAR-08)

Chronic Lymphocytic Leukemia

Spain
Pfizer

Completed

Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)

Rheumatoid Arthritis

United States, Australia, Canada, Israel, Mexico, Colombia, Germany, Russian Federation, South Africa, United Kingdom
The First Affiliated Hospital of Soochow University

Recruiting

Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma

Untreated Mantle Cell Lymphoma

China
Ruijin Hospital

Recruiting

The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk

Diffuse Large B Cell Lymphoma

China
Sun Yat-sen University

Recruiting

Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance With Zanubrutinib for Newly-Diagnosed MCL

Mantle Cell Lymphoma | Newly-diagnosed Mantle Cell Lymphoma

China
Peng Liu

Recruiting

Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL (ZFCR/ZBR)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Newly Diagnosed

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM (ZBR)

Waldenstrom Macroglobulinemia

China
Peng Liu

Recruiting

Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Sun Yat-sen University

Recruiting

A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy

Double Express Diffuse Large B-cell Lymphoma

China
Jing Jin, M.D.

Recruiting

A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk

Rectal Cancer

China
BeiGene

Active, not recruiting

Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

Japan
Swiss Group for Clinical Cancer Research

Terminated

Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular Lymphoma

Lymphoma

Switzerland, Norway, Sweden
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients (FIL_RENOIR12)

Lymphoma, Follicular

Italy
Arbeitsgemeinschaft medikamentoese Tumortherapie

Completed

Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue

Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)

Austria
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab

Lymphoma

United States
Institut Paoli-Calmettes

Completed

Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma (R2)

Non-Hodgkin Lymphoma

France
Roswell Park Cancer Institute
Celgene

Completed

Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant

Lymphoma | Leukemia
University of Bologna

Terminated

Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

Italy
Guangdong Provincial People's Hospital
Guangzhou First People's Hospital; Foshan First People's Hospital; Huizhou Municipal... and other collaborators

Recruiting

Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years (R2DLBCL80)

Diffuse Large B Cell Lymphoma | Age Over 80 Years

China
Peter MacCallum Cancer Centre, Australia
AbbVie

Not yet recruiting

MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (EpLCART)

Relapsed/Refractory Large B-cell Lymphoma

Australia
Weill Medical College of Cornell University
Celgene

Completed

Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Arbeitsgemeinschaft medikamentoese Tumortherapie
Celgene Corporation

Unknown

Lenalidomide in Patients With Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia

Austria
Zhang Lei, MD

Recruiting

Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia

Thrombocytopenia | Antiphospholipid Syndrome | Treatment

China
Ruijin Hospital

Not yet recruiting

Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

China
Enterome

Recruiting

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (SIDNEY)

Follicular Lymphoma | Marginal Zone Lymphoma

United States, Italy, Spain
Kim, Seok Jin
Celltrion; Samyang Biopharmaceuticals Corporation

Recruiting

Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL. (Lemon-C)

Primary CNS Lymphoma

Korea, Republic of
Klinikum Stuttgart
German Federal Ministry of Education and Research; University Hospital Freiburg

Recruiting

OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma (OptiMATe)

Primary Central Nervous System Lymphoma

Germany
Chronic Lymphocytic Leukemia Research Consortium
Celgene Corporation

Unknown

Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia | CLL | Untreated | First-Line | Front-line | Initial Therapy

United States
Innovent Biologics (Suzhou) Co. Ltd.

Withdrawn

Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma

Follicular Lymphoma

China
Incyte Corporation

Active, not recruiting

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)

Follicular Lymphoma | Marginal Zone Lymphoma

Finland, United States, Spain, Korea, Republic of, Canada, Israel, Turkey, United Kingdom, Netherlands, Greece, Italy, France, Taiwan, Germany, Belgium, Japan, Czechia, Switzerland, Ireland, Poland, Ukraine, Australia, Denmark, Hungary, Swede... and more
Tianjin Medical University Cancer Institute and...

Recruiting

A Study of OLR in First-line Treatment of Mantle Cell Lymphoma

Mantle Cell Lymphoma

China
The Lymphoma Academic Research Organisation

Recruiting

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Marginal Zone Lymphoma

France
Yan Zhang, MD
Peking University First Hospital; Chinese PLA General Hospital; Peking University...

Recruiting

Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

Diffuse Large B Cell Lymphoma

China
University of Wisconsin, Madison
Genentech, Inc.; Celgene Corporation

Withdrawn

Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)
Sun Yat-sen University

Recruiting

Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

China
University of Chicago
Celgene Corporation

Completed

Cetuximab and Lenalidomide in Head and Neck

Squamous Cell Carcinoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Celgene Corporation

Terminated

A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer

Colorectal Cancer

Australia, Belgium, Germany, Italy, Spain, Sweden
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital and other collaborators

Terminated

CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
Hackensack Meridian Health
Celgene Corporation

Completed

Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide (FCR)

Chronic Lymphocytic Leukemia (CLL)

United States
Zhang Lei

Recruiting

A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia

Immune Thrombocytopenia | Treatment

China
Lund University Hospital
Mundipharma Pte Ltd.; Roche Pharma AG; Celgene

Completed

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. (LENA-BERIT)

Mantle Cell Lymphoma

Finland, Denmark, Norway, Sweden

3

Subscribe